Doctor of Osteopathy Program year 2022 Reported 2019–2022 Source: CMS Open Payments, 2026 publication

Charles Parent

Family Medicine Kennebunk, ME Doctor of Osteopathy

NPI 1619909249 CMS profile 254888

24 Portland Rd, Kennebunk, ME 04043

Open in the dashboard

General payments

$8,638

616 records reported · program years 2019–2022

Research payments

$0

Paid to them · None reported · program years 2019–2022

Ownership & investment interest

$0

None reported

Through program year 2022, Charles Parent of Kennebunk, ME is reported in the CMS Open Payments database as having received $8,638 across 616 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Family Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2022 General $51 3
2021 General $3,496 223
2020 General $2,276 165
2019 General $2,814 225

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Charles Parent
  • Family Medicine median
  • Middle half of Family Medicine
  • National median

In program year 2025, general payments to Charles Parent were reported at $0. Among 56,786 Family Medicine profiles paid that year, the median was $155 and the middle half received between $45 and $549.

Show as a table
Year Charles Parent Family Medicine median Middle half National median
2019 $2,814 $150 $41–$543 $163
2020 $2,276 $120 $32–$415 $114
2021 $3,496 $137 $35–$551 $132
2022 $51 $137 $37–$512 $149
2023 $0 $149 $42–$545 $160
2024 $0 $156 $44–$560 $164
2025 $0 $155 $45–$549 $169

Breakdown

Who paid General payments · program years 2019–2022
  1. AstraZeneca Pharmaceuticals LP $1,408 70 payments
  2. Pfizer Inc. $925 86 payments
  3. Allergan Inc. $766 78 payments
  4. Salix Pharmaceuticals, a division of Bausch Health US, LLC $624 45 payments
  5. AbbVie, Inc. $620 50 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $609 47 payments
  7. Takeda Pharmaceuticals U.S.A., Inc. $537 43 payments
  8. Novo Nordisk Inc $526 38 payments
  9. GlaxoSmithKline, LLC. $516 35 payments
  10. Lilly USA, LLC $318 22 payments
  11. Other $1,787 102 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2022
  1. Food and Beverage $8,498 612 payments
  2. Education $140 4 payments
Products named General payments · program years 2019–2022
  1. FARXIGA $670 29 payments
  2. SYMBICORT $624 30 payments
  3. ELIQUIS $558 48 payments
  4. VRAYLAR $459 48 payments
  5. Ozempic $420 32 payments
  6. JARDIANCE $398 34 payments
  7. XIFAXAN $386 26 payments
  8. VYVANSE $379 23 payments
  9. RYBELSUS $344 26 payments
  10. UBRELVY $302 25 payments
  11. Other $6,803 515 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

616 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Family Medicine in Maine

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2022

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record